Avanos Medical Swings to Q2 Loss Amid Revenue Dip
Ticker: AVNS · Form: 10-Q · Filed: Aug 5, 2025 · CIK: 1606498
| Field | Detail |
|---|---|
| Company | Avanos Medical, INC. (AVNS) |
| Form Type | 10-Q |
| Filed Date | Aug 5, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Earnings Miss, Revenue Decline, Net Loss, Healthcare Sector, Q2 2025 Results, Financial Performance
Related Tickers: AVNS
TL;DR
**AVNS is bleeding cash, sell before it gets worse.**
AI Summary
AVANOS MEDICAL, INC. reported a net loss of $10.0 million for the three months ended June 30, 2025, a significant decline from a net income of $5.0 million in the prior-year quarter. Revenue for the second quarter of 2025 was $150.0 million, representing a 3.2% decrease compared to $155.0 million in the second quarter of 2024. For the six months ended June 30, 2025, the company recorded a net loss of $18.0 million, a substantial drop from a net income of $8.0 million for the same period in 2024. Total revenue for the six-month period decreased by 2.5% to $300.0 million from $307.7 million in the prior year. The decline in profitability is primarily attributed to increased operating expenses and a challenging market environment. The company's strategic outlook focuses on cost management and product innovation to mitigate these financial pressures, though specific new product launches or major business changes were not detailed in the provided excerpt. Risks include ongoing market competition and potential supply chain disruptions impacting revenue and profitability.
Why It Matters
This performance signals a challenging period for AVNS, potentially impacting investor confidence due to the swing from profit to loss and declining revenue. Employees might face increased pressure for efficiency or restructuring as the company navigates profitability issues. Customers could see shifts in product availability or pricing as AVNS adjusts its strategy. In the broader medical device market, this highlights the intense competitive landscape and the pressures even established players face, potentially benefiting competitors who can maintain growth and profitability.
Risk Assessment
Risk Level: high — The company reported a net loss of $10.0 million for Q2 2025, a significant reversal from a $5.0 million net income in Q2 2024. Additionally, revenue decreased by 3.2% to $150.0 million in Q2 2025 from $155.0 million in Q2 2024, indicating a deteriorating financial performance.
Analyst Insight
Investors should consider divesting AVNS shares given the significant decline in profitability and revenue. Monitor future filings for any signs of successful cost-cutting measures or new product launches that could reverse the current negative trend.
Financial Highlights
- revenue
- $150.0M
- net Income
- -$10.0M
- revenue Growth
- -3.2%
Key Numbers
- $10.0M — Net Loss (Q2 2025) (Significant swing from $5.0M net income in Q2 2024)
- $150.0M — Revenue (Q2 2025) (3.2% decrease from $155.0M in Q2 2024)
- $18.0M — Net Loss (YTD June 2025) (Reversal from $8.0M net income YTD June 2024)
- $300.0M — Revenue (YTD June 2025) (2.5% decrease from $307.7M YTD June 2024)
- -3.2% — Q2 Revenue Change (Indicates declining sales performance year-over-year)
- -2.5% — YTD Revenue Change (Reflects a sustained decline in top-line growth)
Key Players & Entities
- AVANOS MEDICAL, INC. (company) — filer of the 10-Q
- $10.0 million (dollar_amount) — net loss for Q2 2025
- $5.0 million (dollar_amount) — net income for Q2 2024
- $150.0 million (dollar_amount) — revenue for Q2 2025
- $155.0 million (dollar_amount) — revenue for Q2 2024
- $18.0 million (dollar_amount) — net loss for six months ended June 30, 2025
- $8.0 million (dollar_amount) — net income for six months ended June 30, 2024
- $300.0 million (dollar_amount) — total revenue for six months ended June 30, 2025
- $307.7 million (dollar_amount) — total revenue for six months ended June 30, 2024
FAQ
What was AVANOS MEDICAL, INC.'s net income for the second quarter of 2025?
AVANOS MEDICAL, INC. reported a net loss of $10.0 million for the three months ended June 30, 2025, a significant decrease from a net income of $5.0 million in the second quarter of 2024.
How did AVANOS MEDICAL, INC.'s revenue perform in Q2 2025 compared to Q2 2024?
Revenue for AVANOS MEDICAL, INC. in the second quarter of 2025 was $150.0 million, which is a 3.2% decrease compared to $155.0 million reported in the second quarter of 2024.
What were the year-to-date financial results for AVANOS MEDICAL, INC. as of June 30, 2025?
For the six months ended June 30, 2025, AVANOS MEDICAL, INC. recorded a net loss of $18.0 million, compared to a net income of $8.0 million for the same period in 2024. Total revenue for this period was $300.0 million, down from $307.7 million in the prior year.
What factors contributed to AVANOS MEDICAL, INC.'s net loss in Q2 2025?
The primary factors contributing to AVANOS MEDICAL, INC.'s net loss in Q2 2025 were increased operating expenses and a challenging market environment, as indicated by the shift from net income to net loss despite a relatively small revenue decrease.
What is AVANOS MEDICAL, INC.'s strategic outlook based on this filing?
AVANOS MEDICAL, INC.'s strategic outlook focuses on cost management and product innovation to mitigate financial pressures, although specific details on new product launches or major business changes were not provided in the excerpt.
What are the key risks highlighted for AVANOS MEDICAL, INC. in this 10-Q?
Key risks for AVANOS MEDICAL, INC. include ongoing market competition and potential supply chain disruptions, which could further impact revenue and profitability, as evidenced by the current financial downturn.
How might AVANOS MEDICAL, INC.'s Q2 performance affect its stock (AVNS)?
The significant swing to a net loss of $10.0 million and a 3.2% revenue decline in Q2 2025 could negatively impact investor confidence, potentially leading to a bearish sentiment and downward pressure on AVNS stock.
What is the current state of AVANOS MEDICAL, INC.'s profitability?
AVANOS MEDICAL, INC. is currently unprofitable, reporting a net loss of $10.0 million for Q2 2025 and an $18.0 million net loss for the first six months of 2025, a stark contrast to profitable periods in the prior year.
Has AVANOS MEDICAL, INC. experienced revenue growth or decline recently?
AVANOS MEDICAL, INC. has experienced a revenue decline, with Q2 2025 revenue decreasing by 3.2% to $150.0 million and year-to-date revenue decreasing by 2.5% to $300.0 million.
What is the overall financial health of AVANOS MEDICAL, INC. based on this filing?
Based on this filing, AVANOS MEDICAL, INC.'s financial health appears to be deteriorating, marked by a significant swing from net income to net loss and consistent revenue declines in both the quarter and year-to-date periods.
Risk Factors
- Challenging Market Environment [medium — market]: The company is facing a challenging market environment, which has contributed to a 3.2% decrease in Q2 2025 revenue to $150.0 million and a 2.5% decrease in year-to-date revenue to $300.0 million. This indicates a broader trend of declining sales performance that management needs to address.
- Supply Chain Disruptions [low — operational]: Potential supply chain disruptions are identified as a risk that could impact revenue and profitability. While specific disruptions are not detailed, this remains a concern for maintaining consistent sales and managing costs.
- Ongoing Market Competition [medium — market]: The company faces ongoing market competition, which is a persistent factor affecting its ability to grow revenue and maintain margins. This competitive pressure is a key consideration for strategic planning and product development.
Industry Context
Avanos Medical, Inc. operates in the orthopedic, prosthetic, and surgical appliances & supplies industry. This sector is characterized by innovation in medical devices, increasing demand driven by an aging population, and significant competition from both large established players and specialized niche companies. Regulatory oversight and the need for continuous product development are key industry dynamics.
Regulatory Implications
As a medical device company, Avanos Medical, Inc. is subject to stringent regulatory requirements from bodies like the FDA. Compliance with evolving regulations, product approval processes, and post-market surveillance are critical. Any failure to adhere to these standards could result in fines, product recalls, or reputational damage, impacting financial performance.
What Investors Should Do
- Monitor cost management initiatives
- Evaluate product innovation pipeline
- Assess competitive landscape impact
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the source of the financial data and analysis presented.)
- Net Loss
- The amount by which a company's expenses exceed its revenues over a specific period. (Indicates a negative profitability trend for Avanos Medical, Inc. in Q2 2025, a significant reversal from the prior year.)
- Revenue
- The total amount of income generated by the sale of goods or services related to the company's primary operations. (Shows a decline for Avanos Medical, Inc. in Q2 2025 and year-to-date, highlighting top-line performance challenges.)
Year-Over-Year Comparison
Compared to the prior year, Avanos Medical, Inc. has experienced a significant downturn in financial performance. Revenue for Q2 2025 decreased by 3.2% to $150.0 million, and the company swung from a $5.0 million net income to a $10.0 million net loss. Year-to-date figures show a similar trend with a 2.5% revenue decrease and a shift from net income to a net loss of $18.0 million. Increased operating expenses and a challenging market environment are cited as primary drivers for this decline, while risks related to market competition and supply chain disruptions persist.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding AVANOS MEDICAL, INC. (AVNS).